
Zentalis Pharmaceuticals Investor Relations Material
Latest events

Study Update
Zentalis Pharmaceuticals

Q2 2025
6 Aug, 2025

Q1 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Zentalis Pharmaceuticals Inc
Access all reports
Zentalis Pharmaceuticals Inc., operating under the ticker ZNTL on the NASDAQ, is a clinical-stage biopharmaceutical company with a dedicated focus on the discovery and development of small molecule therapeutics aimed at various cancer types. Its pipeline includes a variety of compounds in different stages of clinical trials, targeting key biological pathways in cancer. Zentalis Pharmaceuticals is headquartered in NYC and its shares are listed on the Nasdaq.
Key slides for Zentalis Pharmaceuticals Inc


Jefferies Global Life Sciences Conference
Zentalis Pharmaceuticals Inc


Jefferies Global Life Sciences Conference
Zentalis Pharmaceuticals Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ZNTL
Country
🇺🇸 United States